Skip to content
OpenCapital
Get started

Edwards Lifesciences EW Q2 2025 earnings

Reported July 24, 2025 · After market close

Revenue$1.5BBeat by $44.2MDiluted EPS$0.67Beat by $0.05
Revenue estimate$1.5B
EPS estimate$0.62

Next report

Jul 23, 2026 (In 1 week)
Revenue estimate$1.7B
EPS estimate$0.73

Financials

Q2 2025

Income statement

See full
Revenue$1.5B+11.9%
Gross profit$1.2B+8.6%
Operating income$411.2M+12.2%
Net income$333.2M-9.0%
EPS (diluted)$0.56-8.2%

Balance sheet

See full
Cash & equivalents$3.3B+98.4%
Total debt$702.6M+1.4%
Total equity$10.5B+41.8%
Total assets$13.5B+33.6%

Cash flow

See full
Operating cash flow$290.2M-21.9%
CapEx$49.3M-42.3%
Free cash flow$240.9M-15.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$44.49B-20.1%
Enterprise value$41.91B-23.4%
P/E10.7×-27.1×
P/S7.8×-2.9×

Profitability

See full
Gross margin78.9%-0.7pp
Operating margin25.8%-1.6pp
Net margin73%+44.7pp

Returns & leverage

See full
Return on equity46.1%+24.8pp
Debt / equity0.1×0.0×
Current ratio4.7×+1.0×

Segments

By segment

See full
United States$889.7M+10.3%
Europe$378.2M+13.8%
Rest of World$169.0M+17.1%
Japan$95.3M+10.2%

By product

See full
Transcatheter Aortic Valve Replacement$1.1B+8.9%
Transcatheter Mitral and Tricuspid Therapies$134.5M+62.0%

Versus estimates

Revenue

Q1 2026$1.6BBeat by $51.8MQ4 2025$1.6BBeat by $22.7MQ3 2025$1.6BBeat by $55.3M
Q2 2025$1.5BBeat by $44.2M
Q1 2025$1.4BBeat by $12.2MQ4 2024$1.4BBeat by $26.9M

Diluted EPS

Q1 2026$0.78Beat by $0.05Q4 2025$0.58Miss by $0.04Q3 2025$0.67Beat by $0.07
Q2 2025$0.67Beat by $0.05
Q1 2025$0.64Beat by $0.04Q4 2024$0.59Beat by $0.04

Ask the moment Edwards Lifesciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Edwards Lifesciences report Q2 2025 earnings?
Edwards Lifesciences (EW) reported Q2 2025 earnings on July 24, 2025 after market close.
What were Edwards Lifesciences's Q2 2025 revenue and EPS?
Edwards Lifesciences reported revenue of $1.5B and diluted EPS of $0.67 for Q2 2025.
Did Edwards Lifesciences beat estimates in Q2 2025?
Revenue beat the consensus estimate of $1.5B by $44.2M. EPS beat the consensus estimate of $0.62 by $0.05.
How did Edwards Lifesciences's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.6% from $1.4B a year earlier and diluted EPS declined 4.3% from $0.70.
Where can I find Edwards Lifesciences's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001099800-25-000048) directly on SEC EDGAR. The filing index links above go to sec.gov.